The JAK/STAT signal transducer pathway is responsible for the regulation of numerous inflammatory, hematopoietic and other cell’ growth and differentiation. Inhibition of the JAK signalling resulted in improvement of immune mediated diseases and haematologic disorders, leading to the approval of more jakinibs in recent years. As selectivity of jakinibs does not reach that of biological therapies, their effect and spectrum of adverse effects are broader. First JAK inhibitors were approved in haematologic disorders and rheumatoid arthritis, then baricitinib, upadacitinib, abrocitinib, ritlecitinib became available in dermatological conditions, also in Hungary. The purpose of this review is to overview the immunological and pharmacological effect of jakinibs in order to better understand their action and adverse effects in dermatological immune-mediated disorders. The summary wants to helpin in preventing, monitoring and managing the adverse reactions of JAK inhibitors.
Steuer-Hajdú et al. (Thu,) studied this question.